Related Experiment Video
Updated: Dec 18, 2025
05:34
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
1.4K
Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease
Judy W M Cheng1,2, Vincent Colucci3, James S Kalus4
1MCPHS University, Boston, MA, USA.
The Annals of Pharmacotherapy
|June 16, 2020
Summary
Sodium-glucose cotransporter 2 (SGLT2) inhibitors show cardiovascular benefits for type 2 diabetes patients. Emerging research highlights their potential in managing heart failure and protecting kidneys.
Area of Science:
- Cardiology
- Nephrology
- Endocrinology
Background:
- Sodium-glucose cotransporter 2 (SGLT2) inhibitors are established treatments for type 2 diabetes.
- Large clinical trials reveal significant cardiovascular benefits in patients with type 2 diabetes and established cardiovascular disease or risk factors.
Purpose of the Study:
- To review current and upcoming clinical studies on SGLT2 inhibitors.
- To evaluate the efficacy of SGLT2 inhibitors in heart failure management.
- To assess the renal protective effects of SGLT2 inhibitors.
Main Methods:
- Review of recent and ongoing clinical trials.
- Analysis of data focusing on heart failure and chronic kidney disease outcomes.
- Synthesis of evidence regarding SGLT2 inhibitor mechanisms in these conditions.
Main Results:
- SGLT2 inhibitors demonstrate cardiovascular benefits in type 2 diabetes patients.
- Early evidence suggests benefits for patients with heart failure.
- Positive indications for renal protection in chronic kidney disease.
Conclusions:
- SGLT2 inhibitors represent a promising therapeutic class beyond glycemic control.
- Further research is warranted to fully elucidate their role in heart failure and renal protection.
- SGLT2 inhibitors may offer a multi-faceted approach to managing complex cardiometabolic and renal conditions.
More Related Videos
Related Concept Videos
01:30Heart Failure V: Medical Management
149
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
149
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
796
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
796
01:11Renal Failure: Dose Adjustments
347
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
347
01:22Heart Failure VI: Adjunct Therapies
168
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
168
01:22Heart Failure Drugs: Diuretics
719
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
719
01:22Acute Kidney Injury VI: Nursing Management
278
Acute Kidney Injury (AKI) results in an inability to maintain fluid, electrolyte, and acid-base balance. Effective nursing management is critical in improving patient outcomes and includes comprehensive patient assessment and targeted interventions.Comprehensive Patient AssessmentA detailed history collection is essential, focusing on any recent infections, nephrotoxic medication use, or chronic conditions such as hypertension and diabetes that may contribute to AKI. During the physical...
278